Related Experiment Video
Updated: Aug 14, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
United States' factor XI-deficiency patients need a safer treatment
Louis M Aledort1, Jenny Goudemand,
1Mount Sinai School of Medicine, New York, New York 10029, USA. Louis.aledort@mssm.edu
Abstract:
A replacement factor for Factor XI with is virally inactivated is not available in the U.S. Elsewhere an inactivated concentrate has been used. A review of the experience over 15 years suggests that this product is safe and effective and suggests its potential use in the U.S. The most serious complication of the factor was a slight increase in DIC and thrombotic events.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
